Oak HC/FT general partners Annie Lamont, Andrew Adams and Tricia Kemp invested in healthcare and fintech before the two sectors were mainstream, and today, as a result of that early intuition and a handful of key exits, the trio has over a billion dollars in new fund money to show for it.
The firm announced today that it has secured $1.4 billion for its largest fund to date, an investment vehicle that will exclusively back healthcare and fintech companies. The firm previously raised $500 million, $600 million and $800 million for its other funds, respectively. Doing quick math, Oak HC/FT, which closed its first fund in 2014, has been able to triple its total assets managed in six years.
Over the history of its fund, the team has outlined six notable exits, including Anthem’s acquisition of Aspire Health, Thermo Fisher Scientific’s acquisition of Core Informatics, Diplomat’s acquisition of LDI Integrated Pharmacy Services, AXA Group’s acquisition of Maestro Health, GoDaddy’s acquisition of Poynt and Limeade’s public debut. The firm declined to share any numbers around IRR, or share information on what percent of current portfolio companies are planning to go public and which are best capitalized to do so.
Today’s fund, its fourth to date, will be invested across 20 companies, with average check sizes between $60 million and $100 million. Oak HC/FT invests in both early-stage and growth-stage companies. The fresh capitalization comes during a watershed moment for the two sectors, heavily impacted by the coronavirus pandemic from an innovation and adoption perspective.
For example, digital health funding broke records in 2020, attracting over $10 billion in the first three quarters and increase in deals by investors, compared to the previous year. Fintech, despite an uneven beginning, has been tearing through capital to meet with demand, and valuations continue to skyrocket.
From a healthcare perspective, Adams told TechCrunch that it is looking at startups working on the cost of delivering care and ability to engage with complex patients. Lamont said that “virtualization of [both doctors and patients] has been incredible in the last year,” and that much of the firm’s focus is on startups that rely on providers taking risk. The investor is hinting at the big push of startups that are betting that value-based care will replace fee-for-service care. The former rewards service for money, instead of time for money, placing monetary incentive for doctors more on outcomes than number of visits it takes to get to an outcome.
I asked the team if telehealth was no longer as big of a question mark for them, since the pandemic has accelerated adoption. But Lamont argued that telehealth is still “unbelievably complicated to pull off at scale, which is less obvious to the public.” The firm is looking for startups who can bring a consumer experience to telehealth, taking the place of an in-person receptionist.
The firm is also looking at startups that blend its two expertises, healthcare and fintech, around payments and digitization of billing. Kemp said that the firm is less interested in standalone point-of-sale services for restaurants and bills, and are now looking at items that reduce friction with payments. One of its e-commerce optimization portfolio companies, Rapyd, raised $300 million at a $2.5 billion valuation in January.
Other subsectors of interest include digital consumer payments, as shown by portfolio companies Namogoo and Prove, and fraud and risk identification, as shown by portfolio companies Au10tix and Feedzai.
On the diversity front, Oak HC/FT said that within its portfolio, 26% of C-suite and executive leadership roles are held by women, and 52% of senior management roles are held by women.
The firm has invested in nearly 100 startups to date. Of the 35 investments it made in 2020, 20 of the deals were follow-on rounds.
